Biocad Said to Seek Buyer in Sale That May Top $1 Billion

Biocad, a Russian biotechnology company that’s trying to copy some of the world’s top-selling cancer medicines, is seeking a buyer, said two people with direct knowledge of the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.